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Edited by Robert BaroukiAbstract The steroid receptor RNA activator (SRA) has
previously been characterized as belonging to the growing family
of functional non-coding RNAs. However, we recently reported
the Western blot detection of a putative endogenous SRA protein
(SRAP) in breast cancer cells. Herein, we successfully sup-
pressed the expression of this protein through speciﬁc RNA
interference assay, unequivocally conﬁrming its existence.
Moreover, using database searches and Western blot analysis,
we also showed that SRAP is highly conserved among chordata.
Overall, our results suggest that SRA is the ﬁrst example of a
new class of functional RNAs also able to encode a protein.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Even though RNAs have long been thought to be either
messenger RNAs (mRNAs), transfer RNAs or ribosomal
RNAs, it has become apparent in the last 20 years that many
RNAs do not belong to any of these three subgroups [1]. The
family of non-coding RNAs (ncRNAs), which groups all
RNAs unable to encode a protein, is increasing exponentially
[2]. Data for the new members of this growing family are ac-
tively gathered and corresponding information sorted on
several websites such as http://biobases.ibch.poznan.pl/
ncRNA/, http://rfam.wustl.edu/index.html or http://indiana.
edu/~tmrna/. These RNAs which have no protein coding
capacity have been shown to regulate several cellular processes
as diverse as the subcellular distribution of RNAs and pro-* Corresponding author. Fax: +204-789-3900.
E-mail address: eleygue@cc.umanitoba.ca (E. Leygue).
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Abbreviations: SRA, steroid receptor RNA activator; RNAi, RNA
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tional and translational regulation of gene expression [1,2].
The steroid receptor RNA activator (SRA) has recently been
characterized as one such ncRNA that modulates steroid re-
ceptor transcriptional activity [3].
The originally described SRA sequences diﬀered in their 50
and 30 ends, but were conserved in their central core region [3].
The core region was shown to be necessary and suﬃcient to
increase the ligand-dependent transcriptional activation of
target genes by steroid receptors. None of these original SRA
sequences were successfully translated in vitro or in vivo [3],
and SRA is still currently classiﬁed as belonging to the ex-
panding family of functional ncRNAs [4]. Since 1999, data
have accumulated regarding the possible mechanisms of ac-
tion of SRA RNA. SRA RNA interacts with other proteins
such as the co-repressor Sharp and the AF-1 speciﬁc activator
p72/p68 protein to modulate steroid receptor activity [5,6].
Moreover, SRA RNA potentiates the estrogen-induced acti-
vation of both estrogen receptors a and b [7]. By introducing
mutations in the SRA RNA sequence, Lanz et al. recently
identiﬁed motifs participating in the RNA secondary structure
that are involved in its ability to co-activate progesterone
receptor [8,9].
We recently identiﬁed three new SRA RNA isoforms which
corresponded to SRA except for an additional 37 nucleotides
in the 50 region [10]. This 50 region contains two putative ATG
codons, close together in the same open reading frame, that
could encode putative 236/224 amino-acid SRA proteins
(SRAPs). These isoforms, which contain the functional core
region, encoded a stable protein both in vitro and in vivo.
Using reverse polymerase chain reaction of RNA extracts, we
were able to conﬁrm the presence of these endogenous coding
isoforms in breast cancer cell lines [10]. Furthermore, using an
antibody raised against a peptide corresponding to amino
acids 20–34 of the putative human SRAP, we were able to
speciﬁcally detect a doublet at 30 kDa by Western blot
analysis of total protein lysate from these same cell lines [10].
To date, all other reports describe and discuss human SRA as
a ncRNAmolecule. To our knowledge, no functional RNA has
been described to have a protein coding capacity. It, therefore,
became important to conﬁrm unequivocally the existence of
such an SRAP. In the present study, we demonstrate that the
human SRA gene not only encodes for a protein but that the
sequence of this protein is conserved among vertebrates.blished by Elsevier B.V. All rights reserved.
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2.1. RNA interference (RNAi) vector construction and SRAP
knockdown assay
pSuper.retro-SRA construct was generated by hybridization of oli-
gonucleotides SRARNAif (50-ccccaagtttccctcacgagtcttcaagagagactcg
actgggaaacttgtttt-30) and SRARNAir (50-aaacaagtttcccagtcgagtctctctt
gaagactcgactgggaaacttgggg-30), which were then cloned between the
BglII and HindIII sites of the pSuper.retro vector (Oligoengine, Seat-
tle, WA). The SRARNAi oligonucleotide sequence was selected fol-
lowing analysis with the Oligoengine RNAi design tool (http://
www.oligoengine.com/). HeLa cells were transiently transfected with
either the pSuper.retro-SRA construct or pSuper.retro vector (empty
vector) using the transfection agent Eﬀectene (Qiagen, Missisauga,
ON) according to the manufacturer’s protocol. At indicated times,
cells were washed in 1 PBS and lysed with 2 SDS buﬀer (62.5 mM
Tris, 2% SDS, 10% glycerol, 0.1% bromophenol blue and protease
inhibitor cocktail (Roche, Laval, QB). Protein sample concentration
was determined by the Micro BCA Protein Assay Kit (Pierce, Rock-
ford, IL). Protein samples were analyzed by Western blot.
2.2. Western blot analysis
Proteins were extracted from skeletal tissue [11] or cell lines [10] as
described previously. We chose total skeletal muscle as Lanz et al. [3]
had shown that SRA RNA is highly expressed in human skeletal
muscle. Protein concentration for each sample was determined using
Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA) and equal
amounts of total protein were analyzed by SDS–PAGE and immu-
noblotting. Supernatant samples containing equal amount of total
protein were mixed 1:1 with sample buﬀer [1.25 mM Tris–HCl (pH
6.8), 20% glycerol, 4% SDS, 0.02% (w/v) bromophenol blue and 20
mM DTT], boiled for 5 min, electrophoresed using a 5% stacking gel
and a 10% resolving polyacrylamide gel, and electrophoretically
transferred to nitrocellulose membrane. Membranes were blocked with
5% non-fat dry milk in Tris-buﬀered saline (pH 7.6) and incubated
with rabbit polyclonal antibodies raised against amino acids 20–34 of
human SRA sequence [10] at a dilution of 1:1000 in 5% non-fat dry
milk in Tris-buﬀered saline containing 0.1% Tween. Secondary
horseradish peroxidase-linked goat antirabbit antibodies (1 lg/ll, Bio-
Rad) were then used and signals were analyzed by SuperSignal West
Pico Chemiluminescent Substrate (Pierce). Chemiluminescence signal
was captured by video image analysis using the Quantity One system
(Bio-Rad). To determine equal loading, the SDS–PAGE gels were ei-
ther stained in Coomassie blue solution (50% methanol, 10% acetic
acid and 0.1% w/v Coomassie powder) following transfer or blots were
stripped and reprobed with anti-b-actin antibody (Sigma, Oakville,
ON). In order to detect the speciﬁcity of the detection in the protein
extracts from diﬀerent species, we incubated duplicate blots with anti-
SRA antibody premixed with the peptide used to raise it (1/10 v/v).
2.3. Sequence analysis and database searches
Search of the NCBI protein database (www.ncbi.nlm.nih.gov) led to
the identiﬁcation of the SRA sequences for three species:Homo sapiens
(GenBank Accession Nos. AF293024, AF293025 and AF293026),Mus
musculus (GenBank Accession No. NP_079567) and Rattus norvegicus
(GenBank Accession Nos. NP_000035 and AAG02116). Upon ex-
amining the mouse and rat expressed sequence tag (EST) database, a
longer 50 M. musculus sequence (GenBank Accession No. CB274276)
and a R. norvegicus sequence (GenBank Accession No. CB771552)
were identiﬁed. These sequences were used to deduce the theoretical
sequences for the rat and mouse SRAPs. Search of the Unigene
database and ProtESTs (http://www.ncbi.nlm.nih.gov/UniGene/pro-
test.cgi?SORT¼ 4&ORG¼Hs&XID¼ 114234) led to the identiﬁca-
tion of SRA EST sequences for the following species: Xenopus laevis
(GenBank Accession Nos. BG364002.1, BG551872.1 and
AW642449.1), Silurana tropicalis (GenBank Accession No.
AL969036.1), Sus scrofa (GenBank Accession Nos. CF366666 and
CF368085), and Oryzias latipes (GenBank Accession No.
AU170197.1). We blasted the human SRA3 amino-acid sequence
against the translated EST nucleotide sequences using tblastn, limiting
the search to vertebrates and excluding mouse and human sequences.
This search identiﬁed ESTs for the following additional species: Ma-
caca mulata (GenBank Accession No. CD766957), Equus caballus
(GenBank Accession Nos. B1961443 and B1961063), Bos taurus
(GenBank Accession Nos. CB422540, AW654516, CB450664 andCB457765P), Danio rerio (GenBank Accession Nos. BQ258955,
CB352395), Occhonrhyncus Mykiss (BX860673) and Gallus gallus
(GenBank Accession Nos. CR338992, CR338823, CR338795). Spe-
cies-speciﬁc sequences were assembled using an EST assembler tool
(http://bio.ifom-ﬁrc.it/ASSEMBLY/assemble.html) giving contigs that
were translated using the DNA to amino-acid translational tool (http://
ca.expasy.org/cgi-bin/dna_aa.html). All the putative SRAP sequences
were aligned using the Multalin alignment tool (http://prodes.tou-
louse.inra.fr/multalin/) and two conserved regions were identiﬁed.
These two conserved sequences were used to identify the SRA ana-
logue in Fugu ﬁsh by doing a Blast search against the Fugu ﬁsh ge-
nome. Blast search using the human SRA1 sequence against the
ascidian Ciona intestinalis genome in the TIGR database (http://
tigrblast.tigr.org/tgi/) resulted in the identiﬁcation of an SRA analogue
(GenBank Accession No. BW276199) in C. intestinalis. Blast searched
at the NCBI site http://www-genome.wi.mit.edu/cgi-bin/annotation/
ciona/blast_page.cgi using the C. intestinalis SRA sequence resulted in
a Ciona savignyi SRA analogue. Nuclear localization signals were
search on each individual sequence using Psort II (http://psort.
nibb.ac.jp/form2.html).
2.4. PCR cloning and in vitro translation of rat SRA cDNA
PCR primers (50-agtgagctaccaccccggaa-30 and 50-tatagaagtcatgtg-
aggt-30) designed by analyzing the rat theoretical SRA sequence were
used to amplify cDNA from rat skeletal muscle. The resulting product
was sequenced (GenBank Accession No. AY542868) and cloned in
pcDNA3.1 expression vector. RNA isolation from rat skeletal tissue
and reverse transcription-polymerase chain reaction were conducted as
described previously [9]. pcDNA3.1 (Invitrogen, Carlsbad, CA) ex-
pression plasmid containing either human SRA cDNA or rat SRA
cDNA was used for in vitro translation/transcription reaction.
[35S]methionine labelled SRAPs were generated using wheat germ ly-
sate coupled transcription/translation reactions by the TnT System
(Promega, Madison, WI) according to the manufacturer’s instructions.
The V5-tagged human SRA cDNA construct, previously [10] cloned in
pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA), was used as a positive
control. Lysates were then subjected to SDS–PAGE separation, after
which gels were dried and [35S]methionine labelled protein bands vi-
sualized by exposing overnight to a Molecular ImagerTM-FX Imaging
screen (Bio-Rad) and subsequently scanned using a Molecular Im-
agerTM-FX (Bio-Rad).3. Results and discussion
We were previously able to detect a putative endogenous
SRAP in breast cancer cell lines with an antibody targeted
against amino acids 20–34 of the hypothetical human SRAP
sequence [10]. As we are still today the only ones to have re-
ported the existence of such a putative protein, it became es-
sential to deﬁnitively conﬁrm the identity of the protein
recognized by our antibody. In order to do so, we used the
recently developed RNAi technology in an attempt to
knockdown its expression. Indeed, we reasoned that the spe-
ciﬁc degradation of SRA RNA should result in a decrease in
the expression of the protein recognized by our antibody.
Upon 24 and 48 h, transfection of HeLa cells with a RNAi
speciﬁcally targeted against SRA RNA resulted in a signiﬁcant
decrease in the doublet detected by Western blot and believed
to correspond to the SRAP (Fig. 1A). In contrast and as ex-
pected, RNAi treatments had no signiﬁcant eﬀect on b-actin
levels (Fig. 1B) as well as a non-speciﬁc protein detected by our
anti-SRA antibody (Fig. 1A, 45 kDa). This result links the
expression of the SRA gene to the detection of the suspected
SRAP by Western blot. This unequivocally conﬁrms for the
ﬁrst time the existence of an endogenous SRAP in human cells.
It should be stressed that no noticeable phenotypic changes
were observed in cells treated with SRA-speciﬁc RNAi over
the 48-h post-transfection. This absence of apparent eﬀect
Fig. 2. In vitro translation of human and rat SRA cDNAs. In vitro
transcription/translation reactions were performed using V5-tagged
human SRA cDNA as control (SRA-V5), human SRA cDNA (SRA
Human) and rat SRA cDNA (SRA Rat) as described in Section 2.
Positions of the molecular size markers are indicated on the left.
Fig. 1. Decrease of SRAP expression by RNAi speciﬁcally targeted
against SRA RNA. HeLa cells were transiently transfected with either
SRA RNAi (RNAi) or control (EV) vectors, and SRA or actin protein
expressions assessed by Western blot 24 and 48 h after transfection as
described in Section 2. Positions of the molecular size markers are
indicated on the left.
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nature of these experiments have been conducted. Further
experiments are needed to investigate longer term eﬀects of the
knockdown of SRA gene on phenotypic changes such as
growth rate.
We have then investigated the possible existence of this
SRAP in other species. As of today, Blink, the NCBI sofware
which groups putative species homologues (http://www.
ncbi.nlm.nih.gov/sutils/blink.cgi?pid¼ 9930614), only gathers
human, rat and mouse SRA sequences. Rat SRA sequences
(GenBank Accession Nos. NP_000035 and AAG02116)
correspond to the recently published 146 amino-acid rat SRAP
sequence [12]. This putative rat SRAP sequence was success-
fully translated in vitro and also expressed in vivo when fused
with the C-terminal extremity of green ﬂuorescence protein.
SRAP is much smaller (16 kDa) than the putative human
SRAP we identiﬁed and its endogenous existence has not yet
been demonstrated. Close analysis of the SRAP mRNA se-
quence revealed that it is analogous to the human SRA se-
quences starting at exon 2. We thus suspected the SRAP
mRNA sequence described so far to be incomplete. Indeed,
analysis of the rat chromosome 18 sequence revealed the
presence of a putative additional exon 1 present in a single rat
EST sequence (GenBank Accession No. CB771552). To con-
ﬁrm the existence of this longer SRA sequence, we PCR am-
pliﬁed rat muscle cDNA with speciﬁc primers as described in
Section 2. We cloned a new rat cDNA sequence (GenBank
Accession No. AY542868), which unlike the shorter SRAP
sequence contains two possible methionines possibly initiating
the translation of a 222/230 amino-acid proteins. As shown in
Fig. 2, this sequence is translatable in vitro, generating a visible
doublet at 31/32 kDa. As expected and as a result of an ad-
ditional V5-tag (4.8 kDa), in vitro translated SRA-V5 protein
(35 kDa) has a higher apparent molecular size than the non-
tagged human SRA doublet (30/31 kDa) and rat SRA doublet
(31/32 kDa). As previously described [10], the observed mo-
lecular masses (35, 30/31 and 31/32 kDa) are slightly higher
than those predicted (30.5, 25.7 and 25.3 kDa for the V5-
tagged human, non-tagged human SRAP and rat SRAP,respectively). We hypothesize that the doublet seen for human
and rat SRAPs results from the alternative use of one initiating
methionine instead of another (1 versus 12). Weaker lower
molecular size bands (around 25 kDa) are likely resulting from
translation at internal downstream methionines present in
both the human and rat SRA sequences (see Fig. 3).
Through database analysis, we identiﬁed a M. musculus se-
quence (GenBank Accession No. CB274276), slightly longer
than the one present in the protein database. When translated,
this sequence contains an additional stretch of 12 N-terminal
amino acids, 10 out of which are identical to their corre-
sponding human counterparts (Fig. 3).
In an attempt to identify SRA analogues in other species, we
searched several databases as described in Section 2. Obtained
cDNA sequences were translated and aligned (Fig. 3). The
alignment of putative SRA sequences from diﬀerent species
shows proteins of similar lengths, highly conserved in discrete
domains and in two main regions (amino acids 15–39 and 180–
208 of the human sequence). We have previously demonstrated
that the stably transfected SRAP localizes to the nucleus in
MCF-7 cells [10]. Analysis of the SRA sequences (Psort II), for
nuclear localization signal domains, revealed a conserved pat-7
(P-x-[RK]-[RK]-[RK]) nuclear localization motif in Gallus
(chicken), Oryzias and Occonrhyncus (two ﬁsh) and all the
mammalian putative SRAP sequences (amino acids 155–160).
Interestingly, the two Ciona species which do not contain pat-7
motif at this position, contain however another nuclear lo-
calization pat-4 motif (P-[RK]-[RK]-[RK]) at amino acids 39–
42 with respect to the human SRA sequence.
Overall, putative SRAPs were found in all vertebrates in
which SRA-related EST sequences could be detected. In ad-
dition, putative SRAP analogues were identiﬁed in two Ciona
species, Ciona savignyi and C. intestinalis. Ciona belong to the
urochordata subphylum, which together with Cephalochor-
data and Craniata (contains Vertebrata) subphyla, deﬁnes the
Chordata phylum. We were unable to ﬁnd any sequences clo-
sely related to SRA in any other phyla such as Arthropoda
(Drosophila melanogaster), Nematoda (Caenorhabditis elegans)
or Protobacteria (E. coli). Conservation of the SRAP sequence
from an invertebrate Chordata (Ciona) to a higher vertebrate
(human) suggests an important role possibly played by this
molecule. Furthermore, the conservation of a nuclear locali-
zation signal in most of the SRAPs suggests a nuclear locali-
zation for this putative conserved function. In addition, the
apparent absence of SRA homologues in all non-chordata
phyla suggests that this protein might have been involved in
the emergence of early Chordata.
Fig. 3. Alignment of putative SRAP sequences from several species. SRAP homologues were found as described in Section 2 for the following species:
H. sapiens, B. taurus, M. musculus, R. norvegicus, S. scrofa, E. caballus, M. mulata, G. gallus, O. latipes, O. mykiss, Fugu rubripes, S. tropicalis, X.
laevis, D. rerio, C. intestinalis and C. savignyi. The numbers indicated on top of the alignment correspond to amino-acid sequence of the human SRA
isoform 1. Regions conserved in all species are in dark bold. Boxed regions correspond to partially conserved sequences.
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served in the region between amino acids 15 and 39, we hy-
pothesized that our antibody, raised against the peptide 20–34
of the human SRAP sequence, could recognize SRAPs from
other species. Western blot analysis of SRAP expression was
therefore performed on protein extracted from skeletal muscles(tissue known to contain high levels of SRA RNA [3]) of
several non-human vertebrates.
As shown in Fig. 4A, we were able to speciﬁcally detect a
band of similar size (around 32 kDa) in Bos (cow), Sylvilagus
(rabbit), Sus (pig), Gallus (chicken), Meleagris (turkey) and
Ovis (sheep). Equal amounts of total protein extracts were
Fig. 4. SRAP expression in skeletal muscle of various species. As described in Section 2, Western blots of total protein extracts from the muscle of
diﬀerent species were performed in the absence (A) or presence (B) of neutralizing peptide. Positive control consists of protein extracts from MCF-7
cell line stably expressing V5-tagged human SRA. Positions of the molecular size markers are indicated on the left.
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after transfer (data not shown). Protein extracts from MCF-7
cells stably expressing V5-tagged SRA were used as positive
control (right lane). An upper band corresponding to the
transfected V5-SRA is seen at 35 kDa. In addition, a doublet,
corresponding to the endogenously expressed SRA is seen at
30/31 kDa. No signals were observed when the antibody was
pre-neutralized by the corresponding peptide (Fig. 4B). Inter-
estingly, only one band is detected in muscle extracts, sug-
gesting that only one AUG codon is used to initiate SRAP
translation in these tissues. This may result either from the
existence of only one such codon in the Sus, Bos, Gallus pu-
tative mRNA sequences (see Fig. 3), or from the preferential
tissue-related use of one codon over the other.
No SRAP was detected in the Esox (pickerel) protein ex-
tract. A careful examination of the four hypothetical ﬁsh
sequences we gathered (Fugu, Oryzias, Occhonrhyncus and
Danio) shows that they are similar to the human sequence in
the region recognized by the antibody used (20–34, referenced
to human SRA) except for the presence of a glutamine instead
of a lysine at amino acid 23 (Fig. 3). The Esox SRA sequence,
which remains unknown to date, should, if similar to the other
ﬁsh sequences in this particular region, also contain this par-
ticular amino-acid substitution. Interestingly, our antibody
was able to recognize SRAPs from the Bos (cow) and Gallus
(chicken) tissue extracts despite the presence of a threonine
(Bos) and an alanine (Gallus) instead of a lysine at this same
residue 23. Lysine, alanine and threonine as opposed to glu-
tamine are all hydrophobic amino acids. We therefore suspect
that a switch in the hydrophobicity of the amino acid at resi-
due 23 may be responsible for the impaired recognition of
Esox SRAP by our antibody.
In this study, we have demonstrated that the human SRA
gene encodes for a protein conserved among vertebrates. The
high conservation of SRAP sequence underlines the possible
important role played by this protein. Previous studies have
shown that SRA RNA is fully functional independently of its
protein coding capacity. SRA therefore appears to be the ﬁrst
example of a new class of functional RNAs also able to encode
a protein.The existence of an SRAP raises several important questions
waiting to be addressed. What is the role of SRAP? What are
the implications of SRAP on SRA RNA function? How are
the expressions of SRA RNA and SRAP regulated? What
other molecules function at dual protein/RNA levels? Since all
of the functional studies on human SRA described to date
ignore the existence of a protein, addressing the above ques-
tions is critical to fully understand SRA function. More
importantly, development in our understanding of SRA
RNA and protein function is in turn critical for a change in
the current perspective of functional ‘‘non-coding’’ RNA
molecules.
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